Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Novacyt  /  Zoektocht naar de volgende biotech raket op het gebied van anti-lichaam testing

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

  • 0,630 16 apr 2024 17:35
  • -0,031 (-4,69%) Dagrange 0,604 - 0,690
  • 394.152 Gem. (3M) 112,5K

Zoektocht naar de volgende biotech raket op het gebied van anti-lichaam testing

74 Posts
Pagina: «« 1 2 3 4 | Laatste | Omlaag ↓
  5. Sharoo 5 mei 2020 19:16
    For Jean-Michel CARLE, President and CEO of Eurobio Scientific, "After the launch of our molecular
    biology offers and our automated serology offer, this marketing agreement with NG Biotech perfectly
    complements the diagnostic arsenal that we can make available to our customers to deal with the COVID19 crisis. Eurobio Scientific is proud to enable the rapid commercialization of a solution developed in
    France.

    Als ik het goed begrijp zal Eurobio test voor covid-19 mogen commercialiseren. Wat betekend dit voor het bedrijf zelf? En voor de koers?
  7. [verwijderd] 6 mei 2020 09:51
    quote:

    RW1963 schreef op 6 mei 2020 09:20:

    Intrasense

    actu.fr/occitanie/montpellier_34172/c...
    Mijn Frans is niet bijster goed, maar als ik het zo ff lees lijkt het er op dat ze de software gratis verstrekken.
    Vraag me dan gelijk af waar, op dit moment, de (potentiële) meerwaarde zit voor de aandeelhouder.
  11. [verwijderd] 1 februari 2021 20:46
    quote:

    Blue Chip schreef op 7 november 2020 12:48:

    Sorrento is volgens mij wel een goede kandidaat nu, testresultaten waren goed, koers is nog niet meegegroeid. Heeft iemand die in porto?
    Heb SRNE in m'n portefeuille, beetje laat ingestapt aan $8 maar ondertussen mooi +85%.

    Reden dat ik ze kocht was niet zozeer hun COVID producten (hoewel hot tegenwoordig) maar wat er verder in hun pipeline zit van behandelingen tegen voornamelijk verschillende kankers.

    Zie sorrentotherapeutics.com/research/pip...

    Voorlopig blijven deze in m'n portefeuille ongeacht kortetermijn koersverloop (of ze zouden echt moeten boomen)
  12. [verwijderd] 3 februari 2021 20:15
    Ncyt mcap £580 million vs Braveheart £15 million

    Paraytec's target is to detect less than 1000 virions per millilitre of sample, which would represent a market leading performance"

    "Detection tests show that Paraytec's aptamer based viral capture system completely traps target material in 300 seconds or less, confirming that its test platform is on target to deliver a test result within a five-minute timeframe"

    "We are very pleased with the rapid performance of our sample capture device. Together with the analytical sensitivity and speed of the optical system, we are on track to deliver a robust test that will support the level of infection control required globally."

    "We are very pleased with the rapid performance of our sample capture device" MEANING capture device is well on TRACK and to DELIVER what paraytec / professor have been saying all this time....looks like we are TUNING this device to make it even better and FASTER....WATCH THIS SPACE.....dont get caught out on next rns....which can come much earlier than late FEB

    "Together with the analytical sensitivity and speed of the optical system, we are on track to deliver a robust test that will support the level of infection control required globally."

    "The objective is to develop a portable test, which can generate a result in a matter of minutes from a swab provided at the test location and which requires no specialist skills for its operation. If successful, it could be used in airports, transport hubs, large workplaces and similar settings, where rapid screening of large numbers of people for presence of COVID-19 or any future emerging pandemic, is required."

    braveheartgroup.co.uk/investments/
    nl.investing.com/equities/braveheart-...
  13. forum rang 5 Louis7 7 februari 2021 09:44
    Three UK manufacturers selected to make rapid Covid tests.
    Push to develop domestic diagnostics industry and less reliance on foreign producers.

    February 7, 2021
    The UK government has selected three British companies to make rapid Covid-19 tests, as it seeks to shake off its reliance on foreign producers and create a domestic diagnostics industry that is prepared for future outbreaks of infectious disease.

    The department of health has selected Omega Diagnostics, SureScreen and Global Access Diagnostics to produce up to 2m lateral flow devices (LFDs) per week for the UK, according to two people briefed on the decision.

    The government has been intent on developing a domestic diagnostics industry since early last year when the Covid-19 crisis forced ministers to confront the lack of domestic sources of critical medical resources. In particular, it has been seeking to reduce its reliance on China for key imported goods as part of what has been dubbed “Project Defend”.

    Speaking in front of MPs on Wednesday, Baroness Dido Harding, the head of Test and Trace, said “there is very much an ambition to create a domestic UK manufacturing capacity” for LFDs, tests that provide results in under 30 minutes and have been the subject of fierce criticism.

    As part of this drive, the government last year paid the consulting firm PA Consulting £6.2m to find suitable British manufacturers of LFDs, and to help scale up manufacturing to reach 2m tests a day by April 2021.

    Unlike conventional polymerase chain reaction (PCR) tests, which look for the virus’s genetic material and can take up to a day to process, LFDs do not need to be analysed in a laboratory. The tests look for protein antigens that live on a virus’s surface and work by adding a liquid reagent to a saliva or nasal swab sample.

    £170m Cost of air freight of lateral flow devices tests from China to the UK since the beginning of the pandemic

    A ferocious scientific row has broken out about the accuracy and safety of these tests after several studies found they miss up to 60 per cent of active infections. One group of researchers continues to trumpet the devices as the only viable way of identifying the large portion of the public that experience no symptoms of the disease, while another says they are likely to kill many more people than they save.

    The government, which has doubled down on its rollout of LFDs in spite of the debate, has been almost entirely reliant on limited supplies from the US and China and is desperate to scale up domestic production.

    According to publicly available contracts, it has so far spent at least £1.5bn on the tests — and last month closed a tender worth a further £912m. The bulk of the spending has gone to US company Innova, which has received £1bn in contracts to procure hundreds of millions of devices which are manufactured in China.

    The department of health has spent £170m on air freight of these tests from China to the UK since the beginning of the pandemic, the contracts state.

    Global Access Diagnostics, which currently has 70 employees but is planning to hire another 210 by April, is a high volume manufacturing enterprise in Bedfordshire, which spun out from the diagnostics firm Mologic last year. It has received close to £1m in funding from the UK government and around £10m in equipment, according to Mark Radford, the company’s executive director.

    The company aims to expand its annual production of lateral flow tests from 40m to 250m by early May.

    Recommended
    Why supply chain diversification isn’t all that easy
    SureScreen, a firm based in the east Midlands which has so far supplied 2m lateral flow tests to the UK government, has received £11.3m in funding, according to publicly available contracts.

    Omega Diagnostics, which has bases in Scotland and Cambridge, SureScreen and Global Access Diagnostics all declined to comment on contracts with the government.

    The health department said: “We now have the largest diagnostic network in UK history, and our procurement strategy for testing ensures the UK has the supplies needed to support both the existing symptomatic testing and the expanding programme of asymptomatic testing being carried out.”

    amp.ft.com/content/37011547-c7b1-403b...
74 Posts
Pagina: «« 1 2 3 4 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!